Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 18Thoracic 5Genitourinary 5Dermatologic 4Gastrointestinal 3Gynecologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 101Endometrial Neoplasms 74Uterine Cervical Neoplasms 63Carcinoma, Non-Small-Cell Lung 56Colorectal Neoplasms 50Melanoma 49Triple Negative Breast Neoplasms 42Carcinoma, Renal Cell 41Stomach Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Fallopian Tube Neoplasms 33Breast Neoplasms 33Pancreatic Neoplasms 27Neoplasms 25Esophageal Neoplasms 24Carcinoma, Transitional Cell 24Neoplasm Metastasis 23Carcinoma, Hepatocellular 20Lung Neoplasms 19Carcinoma, Ovarian Epithelial 19Small Cell Lung Carcinoma 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17Prostatic Neoplasms 14Cholangiocarcinoma 13Carcinoma, Merkel Cell 11Kidney Neoplasms 10Mesothelioma 9Uterine Neoplasms 8

Interventions

fludarabine 4aldesleukin 4Cyclophosphamide 4pembrolizumab 2fludarabine phosphate 2Polymerase Chain Reaction 2Gene Expression Profiling 2Counseling 2Bupropion 2Biopsy 2Adoptive Transfer 2entinostat 1bintrafusp alfa protein, human 1Zinc Oxide 1Vorinostat 1Varenicline 1Tomography, X-Ray Computed 1Tobacco Use Cessation Devices 1Taxes 1Surveys and Questionnaires 1Ritonavir 1Radiotherapy 1Psychiatric Rehabilitation 1Nicotine Replacement Therapy 1Nicotine 1NHS-IL12 immunocytokine 1Magnetic Resonance Imaging 1Liquid Biopsy 1Interleukin-2 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × pembrolizumab × Gynecologic × Clear all
NCT04301011 2025-04-23

RAPTOR

Turnstone Biologics, Corp.

Phase 1 Terminated
27 enrolled
DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Oropharyngeal Neoplasms, Skin Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡